European Urology
Publisher: Elsevier · ISSN 0302-2838 · 89 articles
- Re: Aboubacar Kaba, Pratik Kanabur, Jeremie Calais, et al. Performance of [89 Zr]girentuximab PET/CT in Predicting the Presence of Any Renal Malignancy: A Reanalysis of the ZIRCON Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.003
- Reply to Alexander Light, Max Peters, Manit Arya, et al’s Salvage Focal Therapy vs Radical Prostatectomy for Localized Radiorecurrent Prostate Cancer. JAMA Oncol 2026;12:364–73.
- When the Platform Owns the Procedure: Intellectual Property Rights and Robotic Surgery
- Reply to Vallée M, Stangl FP, Wagenlehner F et al’s Letter to the Editor re: Tikkinen KAO, Najafabadi BT, Hajebrahimi S, et al. A Multicenter Randomized Controlled Trial of Antimicrobial Prophylaxis to Prevent Urinary Tract Infections After Shockwave Lithotripsy for Urolithiasis: The APPEAL Trial. Eur Urol 2025;88(6):543–51
- Re: Tikkinen KAO, Najafabadi BT, Hajebrahimi S, et al. A Multicenter Randomized Controlled Trial of Antimicrobial Prophylaxis to Prevent Urinary Tract Infections after Shockwave Lithotripsy for Urolithiasis: The APPEAL Trial. Eur Urol 2025;88(6):543–51
- Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436
- Re: De Luca et al. Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA). Eur Urol 2026;89:246–57
- Re: Emanuele Messina, Antonella Borrelli, Alessandro Sciarra, et al. Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA). Eur Urol 2025;89:246–57
- Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052
- Re: Murthy V, Maitre P, Pal M, et al. Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-invasive Bladder Cancer. J Clin Oncol. In press. http://dx.doi.org/10.1200/JCO-25-02093
- Reply to Antonio Cigliola, Andrea Necchi, and Umberto Capitanio’s Letter to the Editor Re: Metastasis-directed Therapy with or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol 2026;90:13–18
- Re: PSMA PET for Lymph Nodes in Intermediate-risk PC
- Reply to Francesco Barletta, Chiara Mercinelli, Francesco Montorsi, et al. re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. Eur Urol 2026;89:550–551
- Reply to Daoyuan Li’s Words of Wisdom re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette Guérin–naïve Non–Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol 2026;90:176
- Re: Safety and Efficacy of Tranexamic Acid in Urologic Surgery: Results from the International, Randomized, Placebo-Controlled POISE-3 Trial
- Re: Impact of Circulating Tumor DNA and Copy-number Alterations on Clinical Outcome in Relapsed/Refractory Germ Cell Tumors Treated with Salvage High-dose Chemotherapy: BLOG TITLE: Value of ctDNA in Advanced Germ Cell Tumors
- Re: Final Overall Survival Results from EORTC 1333/PEACE-3 Trial of Enzalutamide plus Radium-223 in Metastatic Castration-resistant Prostate Cancer
- Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non–muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely
- Re: Prophylactic Ureteral Stenting in Kidney Transplantation: A Multivariable and Propensity Score-matched Analysis of 3407 Recipients from NSQIP Transplant
- Re: Microultrasonography-guided Versus MRI-guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial
- Re: Philip Cornford, Roderick C.N. van den Bergh, Erik Briers, et al. EAU–EANM–ESTRO–ESUR–ISUP–SIOG Guidelines on Prostate Cancer—2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.04.013
- Re: A Randomized Controlled Trial Comparing En-bloc Versus Lobe-by-lobe HoLEP: Surgical Efficiency and Early Continence Outcomes
- Major Adverse Cardiovascular Events in Men with High-risk Localized or Metastatic Prostate Cancer Starting Long-term Hormone Therapy in the STAMPEDE Trial
- Re: Targeted Prostate Cancer Screening in BRCA1 or BRCA2 Pathogenic Germline Variant Carriers Detects Clinically Relevant Disease: Five-year Results of the IMPACT Study
- Re: Perioperative Apalutamide In High-risk Localized Prostate Cancer
- Re: Aldo Brassetti, Gabriele Tuderti, Umberto Anceschi, et al. Sutureless Purely Off-clamp Robotic Partial Nephrectomy: Evidence from a Randomized Controlled Noninferiority Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.019
- Re: Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Bladder Cancer
- Reply to Dachun Jin, Chi-Fai Ng, and Peter Ka-Fung Chiu’s Letter to the Editor re: Bi-Ming He, Keqin Zhang, Zhien Zhou, et al. Cognitive Versus Software-based Fusion Targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.06.020
- Reply to Sho Todo, Keiichiro Kitahama, and Kentaro Inamura's Letter to the Editor re: Wenxin Xu, Brian I. Rini, Laurence Albiges, et al. Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma. Eur Urol. 2026 Apr 25:S0302-2838(26)02060-9
- 177Lu-Prostate-specific Membrane Antigen Prior to Stereotactic Ablative Radiotherapy in Oligorecurrent Prostate Cancer: Secondary and Exploratory End Point Results from the Randomized Phase 2 LUNAR Trial